Using hydrogel microparticles to improve CAR-T cell therapies for cancer treatment
Hydrogel microparticle technology for high-throughout screening of chimeric antigen receptor-T cells based on single cell effector function
This study is working on improving CAR-T cell therapies for cancer by using special technology to find the best CAR-T cells that can fight tumors, which could lead to better treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Partillion Bioscience Corporation NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10922670 on NIH RePORTER |
What this research studies
This research focuses on enhancing chimeric antigen receptor (CAR)-T cell therapies, which are designed to treat various cancers, including solid tumors. By utilizing hydrogel microparticle technology, the project aims to develop high-throughput screening methods that can analyze individual CAR-T cells based on their functional capabilities. This approach will allow researchers to identify and select the most effective CAR-T cells from a large population, potentially leading to more successful treatments. The study also seeks to connect functional data with genetic information to better understand how to improve CAR-T cell performance in challenging tumor environments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who may benefit from advanced CAR-T cell therapies.
Not a fit: Patients with hematologic malignancies may not benefit directly from this research, as it focuses on solid tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR-T cell therapies, improving treatment outcomes for patients with solid tumors.
How similar studies have performed: Other research has shown promise in enhancing CAR-T cell therapies, but this specific approach using hydrogel microparticles is relatively novel.
Where this research is happening
Los Angeles, United States
- Partillion Bioscience Corporation — Los Angeles, United States (Active)
Researchers
- Principal investigator: De Rutte, Joseph — Partillion Bioscience Corporation
- Study coordinator: De Rutte, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.